Also listed under Genetic Diseases, Inborn, Infant, Newborn, Diseases, Lung Diseases
Cystic Fibrosis clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-06
What changed in the last 30 days
16 trials changed in the last 30 days: 1 stopped, 8 with notable changes, 7 with minor changes only.
- Notable: TMX · Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators Primary completion pushed from Apr 1, 2026 to Jun 30, 2027
- Minor: NUDGE · Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young · Cystic Fibrosis Enrollment closed, study ongoing
- Notable: Gene Modifiers of Cystic Fibrosis Lung Disease Primary and study completion pushed from Jul 2027 to Jul 2028
- Notable: Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease Primary and study completion pushed from Jul 2027 to Jul 2028
- Minor: TIDES 2 · .0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems · Cystic Fibrosis Under 12 Years of Age Primary completion pushed from Aug 31, 2026 to Dec 1, 2026
- Notable: Natural History of Bronchiectasis Primary endpoint(s) modified
- Minor: Relative Bioavailability Study of a VX-581 Tablet Formulation Enrollment closed, study ongoing
- Minor: OnTrackCF · Engagement, Feasibility, and Acceptability Study Trial completed
- Notable: Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2028
- Minor: DANNIgene · Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders Study completion pushed from May 2027 to Jun 2028
- Notable: VX-581 in Healthy Participants and · Cystic Fibrosis Primary and study completion pushed from Nov 19, 2026 to Jul 12, 2027
- Notable: Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Recruitment opened
- Minor: VX-522 · Cystic Fibrosis (CF) Trial completed
- Stopped: ANAKIN · Subcutaneous Administration of Anakinra · CF Trial terminated
- Notable: Regional Phenotyping of CF and Non-CF Bronchiectasis Primary completion pushed from Mar 31, 2026 to Dec 31, 2027
- Minor: HyPOINT · Hyperpolarized Imaging for New Treatments Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-09-09 | NCT07809867 Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis | Istituto Giannina Gaslini new | Phase 4 |
Active trials by phase
| Early Phase 1 | 5 | |
| Phase 1 | 10 | |
| Phase 1/2 | 2 | |
| Phase 2 | 13 | |
| Phase 2/3 | 2 | |
| Phase 3 | 8 | |
| Phase 4 | 9 |
Not charted: 160 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Vertex Pharmaceuticals Incorporated (8) · Children's Hospital Medical Center, Cincinnati (7) · University of North Carolina, Chapel Hill (5) · Hospices Civils de Lyon (4) · Johns Hopkins University (4) · Riphah International University (4) · Royal Brompton & Harefield NHS Foundation Trust (4) · The Hospital for Sick Children (4) · University of British Columbia (4) · Chris Goss (3)
Get alerts when Cystic Fibrosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.